Table 1 Demographic and clinical data at baseline in the intention-to-treat population
Characteristic | N = 99 |
|---|---|
Male, n (%) | 66 (66.7) |
White/Caucasian ethnicity, n (%) | 98 (99.0) |
Median age, years (range) | 64.1 (34-82)) |
ECOG status, n (%) | |
0 | 51 (51.5) |
1 | 48 (48.5) |
Tumor status at diagnosis, n (%) | |
T1 | 1 (1.0) |
T2 | 6 (6.1) |
T3 | 43 (43.4) |
T4 | 25 (25.3) |
Unknown | 24 (24.2) |
Node status at diagnosis, n (%) | |
N0 | 22 (22.2) |
N1 | 24 (24.2) |
N2 | 25 (25.3) |
Unknown | 28 (28.3) |
Metastases status at diagnosis, n (%) | |
M0 | 21 (21.2) |
M1 | 76 (76.8) |
Unknown | 2 (2.0) |
Primary tumor site, n (%) | |
Colon | 59 (59.6) |
Rectum | 40 (40.4) |
Metastases sites*, n (%) | |
Liver | 87 (87.9) |
Lung | 39 (39.4) |
Lymph nodes | 27 (27.3) |
Other | 17 (17.1) |
Prior therapy, n (%) | |
Adjuvant chemotherapy (FOLFOX) | 9 (9.1%) |
Neoadjuvant chemo-radiotherapy for rectal cancer | 7 (7.1%) |
Surgery | 48 (48.5%) |